About Transmembrane protein 266
Transmembrane protein 266 (TMEM266) is a protein
from Homo sapiens identified by UniProt accession
Q2M3C6, 523 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Transmembrane protein 266 |
| UniProt accession | Q2M3C6 |
| Gene | TMEM266 |
| Organism | Homo sapiens |
| Length | 523 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- protein measurement · score 0.32
- creatinine measurement · score 0.32
- cystatin C measurement · score 0.29
- body mass index · score 0.20
- mean corpuscular hemoglobin concentration · score 0.19
- hematocrit · score 0.18
- serum urea measurement · score 0.17
- uric acid measurement · score 0.17
- heel bone mineral density · score 0.12
- glomerular filtration rate · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q2M3C6-F1 | alphafold | PREDICTED | 53.86 | — |
Amino-acid sequence (523 residues)
MTNPQPAIEG GISEVEIISQ QVDEETKSIA PVQLVNFAYR DLPLAAVDLS TAGSQLLSNL DEDYQREGSN WLKPCCGKRA AVWQVFLLSA SLNSFLVACV ILVVILLTLE LLIDIKLLQF SSAFQFAGVI HWISLVILSV FFSETVLRIV VLGIWDYIEN KIEVFDGAVI ILSLAPMVAS TVANGPRSPW DAISLIIMLR IWRVKRVIDA YVLPVKLEME MVIQQYEKAK VIQDEQLERL TQICQEQGFE IRQLRAHLAQ QDLDLAAERE AALQAPHVLS QPRSRFKVLE AGTWDEETAA ESVVEELQPS QEATMKDDMN SYISQYYNGP SSDSGVPEPA VCMVTTAAID IHQPNISSDL FSLDMPLKLG GNGTSATSES ASRSSVTRAQ SDSSQTLGSS MDCSTAREEP SSEPGPSPPP LPSQQQVEEA TVQDLLSSLS EDPCPSQKAL DPAPLARPSP AGSAQTSPEL EHRVSLFNQK NQEGFTVFQI RPVIHFQPTV PMLEDKFRSL ESKEQKLHRV PEA
Explore Transmembrane protein 266 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets